Intestinal barrier integrity enhancement

The intestinal barrier is a complex physiological structure consisting of a mucus layer, a single layer of columnar epithelial cells, and the underlying lamina propria, which serves as the primary interface between the host and the external environment (Vancamelbeke & Vermeire, 2017). Enhancement of intestinal barrier integrity refers to the therapeutic strengthening of this barrier, primarily through the regulation of tight junction (TJ) proteins—such as claudins, occludin, and zonula occludens-1 (ZO-1)—which control the paracellular movement of ions and solutes (Schoultz & Keita, 2020). Dysregulation of this barrier, often termed "leaky gut," allows for the translocation of luminal antigens and pathogens, contributing to the pathogenesis of inflammatory bowel disease (IBD), celiac disease, and systemic inflammatory states (Gopalakrishnan et al., 2012). Pharmacological interventions include glucagon-like peptide-2 (GLP-2) analogs like teduglutide, which promote mucosal growth and barrier function, and zonulin antagonists like larazotide acetate, which stabilize tight junctions (Jeppesen, 2012). These therapies aim to restore intestinal homeostasis and prevent the chronic immune activation associated with barrier breakdown. Monitoring of barrier function is typically performed using biomarkers such as serum zonulin or the lactulose/mannitol ratio (Schoultz & Keita, 2020).

Other names

Gut barrier functionIntestinal mucosal barrierIntestinal permeability regulationEpithelial barrier integrity

Enhancement of the intestinal barrier is achieved by increasing the expression and assembly of tight junction proteins (claudins, occludin, ZO-1), stimulating epithelial cell proliferation and crypt growth via GLP-2 receptor signaling, and inhibiting pathways like MLCK that cause junctional disassembly (Vancamelbeke & Vermeire, 2017).